Inflammatory bowel disease (IBD), which is generally thought to develop from a dysregulated immune response to the gut luminal biota, includes two main forms: Crohn's disease (CD) and ulcerative colitis. Both genetic and environmental factors contribute to the development of CD 1 . Genome-wide association studies (GWAS) for CD have identified over 40 susceptibility loci [2] [3] [4] . The large number of susceptibility genes probably reflects the complexity of the inflammatory process that takes place along the gastrointestinal tract in IBD. The lymphoid tissue in the gastrointestinal tract constantly encounters commensal microbiota as well as potentially pathogenic bacteria; hence, it is critical that a delicate balance be maintained between immune responsiveness and tolerance at this location. Research on susceptibility genes identified by GWAS has exemplified this and has yielded important insights into the pathogenesis of IBD. For example, the immunoregulatory function of regulatory T cells, autophagy and signaling events via interleukin 23 (IL-23) and its receptor have been linked to IBD 5 . Despite such progress, the products of most susceptibility genes have no known mechanism to explain their involvement with CD.
Leucine-rich repeat kinase 2 (LRRK2; also known as dardarin) is encoded by a major susceptibility gene for CD and ulcerative colitis 2, 3, 6 . LRRK2 is a 2,527-amino acid (286-kilodalton), mainly cytoplasmic protein with several functional domains, including leucine-rich repeats (LRRs), a ROC domain ('Ras of complex proteins'), a COR domain ('C-terminal of ROC'), a kinase domain and a WD40-repeat domain. LRRK2 has been identified as the gene mutated most frequently in autosomal dominant familial Parkinson's disease, but the pathological functions of LRRK2 in that context are not well understood 7, 8 . Many single-nucleotide polymorphisms (SNPs) in the LRRK2 locus have been associated with CD by GWAS. A rare SNP (rs11175593) in the noncoding region of LRRK2 is associated with the disease with a P value of 3.08 × 10 −10 (odds ratio, 1.54) 2 . Those findings have been verified by independent meta-analyses of the GWAS 3, 6 . Searching for a pathogenic function for LRRK2 requires careful examination of subtle effects, because most of the common variants identified by GWAS have thus far been shown to have quantitatively small effects on protein expression or biochemical activities. Disease susceptibility is due to the combined effects of multiple independent loci. In the gastrointestinal tract of patients with CD, LRRK2 expression is restricted to lamina propria macrophages, dendritic cells (DCs) and B lymphocytes 9 . Furthermore, LRRK2 expression is induced by interferon-γ, consistent with the idea that it may have a role in IBD 9 . LRRK2 may also affect the production of reactive oxygen species, which would indicate in a role in antimicrobial activities 9 . The complex domain structure of LRRK2 suggests that it may be an important orchestration node in cellular regulation, but how it participates in the molecular mechanisms of CD pathogenesis is not clear.
NFAT comprises a family of transcription factors important for regulating immune responses. NFAT was originally identified as a transcription factor in T lymphocytes that regulates expression of the gene encoding IL-2 by translocating from the cytoplasm to the nucleus, where it actively binds cognate DNA motifs at enhancer sites in response to Ca 2+ influx triggered by antigen recognition 10 . NFAT1 regulates innate immune responses in macrophages, DCs and neutrophils, in addition to having well-recognized roles in T cell cytokine production, neuronal differentiation, stem cell maintenance
The kinase LRRK2 is a regulator of the transcription factor NFAT that modulates the severity of inflammatory bowel disease Leucine-rich repeat kinase 2 (LRRK2) has been identified by genome-wide association studies as being encoded by a major susceptibility gene for Crohn's disease. Here we found that LRRK2 deficiency conferred enhanced susceptibility to experimental colitis in mice. Mechanistic studies showed that LRRK2 was a potent negative regulator of the transcription factor NFAT and was a component of a complex that included the large noncoding RNA NRON (an NFAT repressor). Furthermore, the risk-associated allele encoding LRRK2 Met2397 identified by a genome-wide association study for Crohn's disease resulted in less LRRK2 protein post-translationally. Severe colitis in LRRK2-deficient mice was associated with enhanced nuclear localization of NFAT1. Thus, our study defines a new step in the control of NFAT activation that involves an immunoregulatory function of LRRK2 and has important implications for inflammatory bowel disease.
1 0 6 4 VOLUME 12 NUMBER 11 NOVEMBER 2011 nature immunology A r t i c l e s and cardiac development [11] [12] [13] [14] [15] [16] [17] . The NFAT family consists of five members (NFAT1-NFAT5). With the exception of NFAT5, which is regulated by osmotic stress 18 , NFAT family members are believed to be governed chiefly by calcium signals that control their phosphorylation state 10 . Cytoplasmic, inactive NFAT proteins are generally excluded from the nucleus through the phosphorylation of specific serine residues by various serine-threonine kinases. Cell stimuli that trigger Ca 2+ influx activate the phosphatase calcineurin, which removes the regulatory phosphate groups and allows the translocation of NFAT to the nucleus 10, 19 . In addition to that central control pathway, a protein-RNA complex composed of the large noncoding RNA NRON (an NFAT repressor) and 11 additional proteins has been shown to be associated with cytoplasmic NFAT 20 . Overexpression studies have shown that the complex directly inhibits the translocation of NFAT to the nucleus independently of phosphorylation 20 . Whether this complex regulates trafficking of NFAT to the nucleus in response to specific cellular inducers remains unknown.
Here we investigated the role of LRRK2 in IBD and the underlying molecular mechanism of this association. Various experimental mouse models have been established to study the roles of the innate and adaptive immune systems in the pathogenesis of IBD. Given the predominant expression of LRRK2 in cells of the innate immune response but not in T cells 21 , we used a model of colitis induced by dextran sulfate sodium (DSS) in this study. Acute colitis induced by DSS depends on the innate immune system, because it occurs in mice of the severe combined immunodeficiency strain, which lack B lymphocytes and T lymphocytes 22 . Here we found that deficiency in LRRK2 exacerbated colitis in mice treated with DSS. We searched for potential mediators of the effect using data from an RNA-mediated interference (RNAi) screen of Drosophila melanogaster and found that LRRK2 was an interaction partner of NFAT. We found that LRRK2 inhibited NFAT1 activation not by altering phosphorylation of NFAT1 but by potently modulating the cytoplasmic retention of NFAT and the interaction between NFAT1 and the NRON complex in response to selected inducers such as lipopolysaccharide (LPS). Finally, an LRRK2 risk allele associated with CD in humans resulted in slightly less LRRK2 protein and subtly enhanced NFAT activity, consistent with its role in multifactorial susceptibility to human IBD.
Collectively, our data demonstrate that LRRK2 negatively regulates NFAT-driven innate immune responses in myeloid cells and that smaller amounts of LRRK2 in humans provide molecular insights into how this protein can contribute to a greater risk of CD.
RESULTS
Enhanced susceptibility of Lrrk2 −/− mice to DSS-induced colitis Lrrk2 −/− mice on the C57BL/6 background did not develop spontaneous IBD and had a normal gastrointestinal tract ( Supplementary  Fig. 1 ). DSS-induced colitis, a widely used model for experimental IBD, reflects the contributions of cells of the innate immune response and cells of the myeloid lineage in response to acute mucosal damage [22] [23] [24] [25] . LRRK2 had higher expression in bone marrow-derived macrophages (BMDMs) and bone marrow-derived DCs than in CD4 + T cells 21 (Fig. 1a and Supplementary Fig. 2 ), so we examined the colitis induced in Lrrk2 −/− and wild-type C57BL/6 mice by the administration of 3% DSS for 8 d. Lrrk2 −/− mice developed more severe clinical symptoms of IBD, including rapid weight loss, severe diarrhea and bloody stools (Fig. 1b) . We observed with similar effects after treatment with 5% DSS (Supplementary Fig. 3 ). Histological analysis of the colons showed more severe disease, including massive inflammatory infiltrates, thickened walls and disruption of mucosal structures, in Lrrk2 −/− mice (Fig. 1c,d ). The production of the inflammatory cytokines IL-12 (p40 subunit (IL-12p40)) and IL-6 after DSS treatment was greater in Lrrk2 −/− mice than in wild-type mice (Fig. 1e) . Thus, LRRK2 deficiency exacerbated colon inflammation in DSS-treated mice.
LRRK2 deficiency in hematopoietic cells exacerbates colitis
To assess the association of the colitis exacerbation in Lrrk2 −/− mice with hematopoietic cells, we reconstituted sublethally irradiated wildtype mice with total bone marrow cells from wild-type or Lrrk2 −/− mice. After treatment with 3% DSS, mice that received Lrrk2 −/− bone marrow cells developed more rapid and severe colitis, including weight loss, diarrhea and bloody stools, than did mice that received wild-type bone marrow (Fig. 1f) . Furthermore, we found that mice that received a 1:1 mixture of wild-type and that received solely wild-type bone marrow or those that received only Lrrk2 −/− bone marrow ( Supplementary Fig. 4 ). These data suggested that LRRK2 deficiency intrinsic to the hematopoietic cells exacerbated colitis, consistent with the observation that LRRK2 is not expressed in intestinal epithelial cells 9 .
LRRK2 is a negative regulator of NFAT1 LRRK2 is a complex protein with a variety of functional domains. To gain insight into the molecular functions of LRRK2, we did an in silico search for dLRRK (DRSC15816), the D. melanogaster ortholog of LRRK2, in the RNAi phenotype database of the Drosophila RNAi Screening Center at Harvard Medical School. We found that dLRRK was assigned a score as a weak 'hit' in a screen for regulators of the translocation of NFAT to the nucleus but had no role in other signaling pathways, such as Jak-STAT, MAPK or Wnt-Wingless 26 .
Because the small interfering RNA screen indicated that LRRK2 was able to suppress NFAT activity, we tested the effect of LRRK2 overexpression on NFAT activation in HEK293T human embryonic kidney cells. LRRK2 specifically inhibited NFAT-dependent transcriptional activity in a functional luciferase reporter assay (Fig. 2a) . Moreover, in contrast to a published report 9 , we did not observe any effect of LRRK2 on the activity of a reporter for the transcription factor NF-κB in this cell type. We stably transfected HEK293T cells with a DNA construct encoding LRRK2 under the control of a promoter regulated by doxycycline. As expected, treatment with doxycycline resulted in substantial LRRK2 expression in these cells (Fig. 2b) . By confocal microscopy we observed considerable nuclear translocation of an ectopically expressed fusion protein of NFAT1 and green fluorescent protein (NFAT1-GFP) in response to ionomycin-induced Ca 2+ flux in HEK293T cells (Fig. 2b) . However, LRRK2 overexpression caused nearly complete retention of NFAT1-GFP in the cytosol despite stimulation with ionomycin ( Fig. 2b,c) . We also observed inhibition of the translocation of NFAT1-GFP to the nucleus by LRRK2 in fractionated lysates from HEK293T cells transiently overexpressing NFAT1-GFP with or without Myc-tagged LRRK2 (Myc-LRRK2; Supplementary Fig. 5a ). Together these data showed that LRRK2 suppressed the transcriptional activity of NFAT1 by preventing its translocation to the nucleus. We observed a similar inhibitory effect for other members of the NFAT family, including NFAT2, NFAT3 and NFAT4 ( Supplementary Fig. 5b-d) .
To evaluate whether LRRK2 regulates NFAT1 endogenously, we treated BMDMs from wild-type and Lrrk2 −/− mice with various concentrations of ionomycin and assessed the translocation of NFAT1 to the nucleus by fractionation and immunoblot analysis. LRRK2 deficiency led to enhanced translocation of NFAT1 to the nucleus after treatment with ionomycin ( Fig. 2d) . Those data led us to investigate whether this translocation was altered in the DSS-colitis model. By immunohistochemical staining, we observed much more localization of NFAT1 to the nucleus in colon sections from Lrrk2 −/− mice treated with DSS but not in those from wild-type mice treated with DSS (Fig. 2e) . These data indicated that LRRK2 retained NFAT1 in the cytoplasm.
LRRK2 inhibits NFAT by modulating the NRON complex
To determine whether the kinase activity of LRRK2 was required for NFAT1 regulation, we measured NFAT-driven luciferase activity in HEK293T cells transfected to express wild-type LRRK2 or LRRK2 without kinase activity ('kinase-dead' LRRK2) 27 . Both wild-type and kinase-dead LRRK2 had similar inhibitory effects on NFAT activity (Fig. 3a) , which suggested a kinase-independent mechanism. Various phosphorylation states of NFAT1 can be distinguished by their relative mobility in migrating through SDS-polyacrylamide gels 28 . We treated cells with a pulse of ionomycin, which leads to a faster migrating NFAT1 band, then washed away the ionomycin to allow rephosphorylation of NFAT1, which causes it to migrate more slowly. Overexpression of Myc-LRRK2 did not enhance the phosphorylation of NFAT1-GFP but (Fig. 3b) . That observation, along with the result reported above showing kinase-independent inhibition, excluded the possibility that LRRK2 might inhibit NFAT1 by either direct or indirect phosphorylation. We next investigated whether LRRK2 affected the predominant nuclear localization of a constitutively active form of NFAT1 (caNFAT1) in which the serine residues in the regulatory domain were replaced with alanine 29 . In HEK293T cells stably expressing doxycycline-inducible V5-tagged LRRK2 (V5-LRRK2), V5-LRRK2 impeded the translocation of caNFAT1-GFP to the nucleus, as assessed by confocal microscopy (Fig. 3c,d ). These observations indicated that LRRK2 directly controlled the translocation of NFAT to the nucleus independently of regulation of its phosphorylation. We also demonstrated the inhibitory effect of LRRK2 on caNFAT1 in cytosolic and nuclear fractions from cells transiently overexpressing Myc-LRRK2 (Fig. 3e) . Together these data suggested that LRRK2 constrained the translocation of NFAT to the nucleus by a dominant inhibitory regulatory mechanism independently of phosphorylation.
We investigated whether the LRRK2-mediated regulation could be connected to the NRON complex, which directly inhibits translocation of NFAT to the nucleus. To determine whether LRRK2 was physically associated with the protein-NRON complex, we overexpressed Myc-LRRK2 in HEK293T cells and immunoprecipitated it with antibody to Myc (anti-Myc). Five of the eleven proteins that constitute the NRON complex, including IQGAP1, CSE1L, TNPO1, PPP2RA and PSMD11, immunoprecipitated together with Myc-LRRK2 ( Fig. 4a  and Supplementary Fig. 6 ). We also detected the regulatory noncoding RNA NRON in association with LRRK2 by immunoprecipitation followed by RT-PCR with NRON-specific primers (Fig. 4b) . Knockdown of NRON abrogated the binding between Myc-LRRK2 and NFAT1-GFP and released the inhibition of Myc-LRRK2 on the translocation of NFAT1-GFP to the nucleus ( Supplementary  Fig. 7) . Moreover, LRRK2 overexpression enhanced the association of NFAT1 with IQGAP1, CSE1L and TNPO1 after direct immunoprecipitation of NFAT, whereas the proportion of bound PPP2R1A remained unchanged (Fig. 4c) . There was no coimmunoprecipitation of NFAT1-GFP and PSMD11 with or without Myc-LRRK2 (Fig. 4c) .
Proteins of the NRON complex also interacted with endogenous LRRK2 in THP-1 human monocyte cells (Fig. 4d) . The findings reported above suggested that LRRK2 might act as a dynamic regulator of the localization of NFAT1 to the nucleus and that changes in LRRK2 in response to extrinsic signals might have a regulatory role in immune responses. We therefore determined what regulates LRRK2 protein, especially at the post-translational level. LPS is a stimulus commonly used to activate macrophages; however, LPS alone does not activate NFAT1 (ref. 30) . We treated BMDMs with various doses of LPS and observed much less LRRK2 within 1 h (Fig. 4e) . Furthermore, we found that pretreatment of BMDMs with LPS enhanced the translocation of NFAT1 to the nucleus induced by ionomycin (Fig. 4f) . Thus, the amount of LRRK2 protein was actively regulated in response to innate immune stimuli such as LPS in BMDMs.
LRRK2 negatively regulates macrophage activation
We next investigated the effect of LRRK2 on NFAT1 inhibition in BMDMs by examining the production of proinflammatory cytokines after exposure to various stimulators of innate immunity ( Fig. 5a and Supplementary Fig. 8) . Zymosan, a cell-wall constituent of Candida species commonly found in gut luminal flora, activates NFAT1-dependent cytokine production in macrophages by a mechanism that is dependent on the C-type lectin receptor dectin-1 but independent of Toll-like receptor 2 (ref. 31). We therefore examined cytokine production induced by zymosan in wild-type and Lrrk2 −/− BMDMs. For comparison, we also stimulated BMDMs with another agonist of Tolllike receptor 2, Pam 3 CSK 4 , which does not activate NFAT1 in macrophages. Lrrk2 −/− BMDMs secreted more IL-12p40 and IL-6 than did wild-type BMDMs in response to zymosan but not in response to Pam 3 CSK 4 (Fig. 5a) . In contrast, cytokine production (IL-12 and IL-6) was similar in wild-type and Lrrk2 −/− BMDMs treated with other stimulators (Supplementary Fig. 8a,b) . In addition, LRRK2 deficiency did not affect the production of tumor necrosis factor (TNF) or the inflammasome-dependent release of IL-1β (Fig. 5a) . To further determine the role of LRRK2 in macrophage activation in vivo, we challenged wild-type and Lrrk2 −/− mice with zymosan or Pam 3 CSK 4 . Treatment with zymosan resulted in more upregulation of IL-12p40 and IL-6 in Lrrk2 −/− peritoneal macrophages than in wildtype peritoneal macrophages (Supplementary Fig. 8c) . Treatment with the calcineurin inhibitor FK506 resulted in much less production of IL-12p40 and IL-6 in wild-type and Lrrk2 −/− BMDMs (Fig. 5b) , which suggested that the production of these cytokines in response to zymosan could be NFAT dependent. Indeed, immunoblot analysis of nuclear and cytosolic fractions showed greater accumulation of NFAT1 in the nucleus of Lrrk2 −/− BMDMs than in the nucleus of wild-type cells after treatment with zymosan (Fig. 5c) . In contrast, LRRK2 deficiency did not substantially alter the NF-κB or MAPK signaling cascade (Supplementary Fig. 9 ). We conclude that LRRK2 is a selective endogenous modulator of the degree of NFAT1-induced cytokine responses to inducers of the innate immune response, such as zymosan.
On the basis of those observations, we speculated that LRRK2 deficiency accelerated DSS-induced colitis through greater activation of NFAT1 in macrophages. We therefore determined whether blocking NFAT1 by inhibiting calcineurin with cyclosporin A (CsA) would alleviate the colitis exacerbated by LRRK2 deficiency. CsA has been used to treat DSS-induced colitis in mice 32, 33 . However, its protective effect has been attributed to inhibition of leukocyte recruitment and upregulation of transforming growth factor-β rather than an effect on NFAT activation 34, 35 . Treatment with CsA ameliorated the weight loss and clinical symptoms of colitis very effectively (Supplementary Fig. 10a) . We observed few infiltrating inflammatory cells in colon tissues from CsA-treated mice ( Supplementary  Fig. 10b ). Immunohistochemical analysis showed that CsA treatment potently inhibited the localization of NFAT1 to the nucleus in infiltrating cells from Lrrk2 −/− mice (Supplementary Fig. 10b) . Thus, modulation of NFAT1 activation provides an additional explanation for the efficacy of CsA treatment in colitis 34, 35 , especially in Lrrk2 −/− mice. These results indicated that NFAT can be regulated by calcineurin in the absence of LRRK2 and confirmed in vivo that the two regulatory steps are independently controlled.
CD-associated allele results in less LRRK2 protein Genome-wide meta-analysis of three studies of CD has identified several SNPs at the LRRK2 locus (P < 5 × 10 −5 ) 2 . One of the polymorphisms, rs3761863, which associates with CD with a P value of 3.49 × 10 −5 , leads to a point mutation at position 7190 (cytidine to thymidine); this results in the substitution of methionine for threonine at amino acid position 2397 (Met2397), which does not affect the kinase activity of LRRK2 (ref. 36) . We investigated whether this mutation (the 'M2397 allele') affected the amount of LRRK2 protein when expressed in HEK293T cells, which lack endogenous LRRK2. The high-risk M2397 allele led to a subtle but highly reproducible lower abundance of LRRK2 protein than did the low-risk allele encoding the 
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Thr2397 variant of LRRK2 (the 'T2397 allele'), when transiently overexpressed in HEK293T cells (Fig. 6a) . In addition, LRRK2 Met2397 showed less stability in a cycloheximide chase assay (Fig. 6b) . The lower abundance of LRRK2 Met2397 could be ascribed to its halflife of approximately 8 h compared with the half-life of ≥18 h for the LRRK2 Thr2397 variant. To determine whether the polymorphism altered the amount of endogenous LRRK2 protein, we compared cytoplasmic extracts of B cells purified from peripheral blood from four people homozygous for the M2397 allele or the T2397 allele. People homozygous for the M2397 allele had significantly less LRRK2 protein than did those homozygous for the T2397 allele (Fig. 6c) , whereas there was no substantial difference between these groups in the amount of mRNA encoding LRRK2 (Supplementary Fig. 11 ). Finally, we compared the NFAT-activation ability of the LRRK2 variants in a functional luciferase assay. The product of each allele inhibited the transcriptional activity of NFAT, but the inhibitory effect of LRRK2 Thr2397 was slightly greater than that of LRRK2 Met2397, which correlated with more LRRK2 Thr2397 protein (Fig. 6d) . Several analyses showed that there was a slightly but significantly less NFAT activity with a greater degree of stimulation (0.5 or 1 µM ionomycin) in cells expressing the LRRK2 Thr2397 variant (P < 0.05). Thus, the modestly greater abundance of LRRK2 Thr2397 protein caused detectable changes in NFAT activation. We further compared the cytokine production after stimulation in cultured macrophages generated from people homozygous for the M2397 allele or T2397 allele. Our preliminary results indicated that macrophages from people homozygous for the M2397 allele have more cytokine production in response to stimuli of the innate immune response such as zymosan (Supplementary Fig. 12 ), but these findings must be confirmed with a larger number of subjects. Therefore, these data suggest that a single amino acid caused a delicate shift in the genetically determined amount of LRRK2 protein, which led to subtly heightened NFATdriven inflammatory responses, thereby potentially accounting for the greater risk of CD associated with the M2397 allele in humans.
DISCUSSION
Here we have shown that LRRK2 negatively regulated NFAT1 and that LRRK2 deficiency in mice caused hyperactive immune responses and greater susceptibility to DSS-induced IBD. We became interested in the regulation of NFAT by LRRK2 because of an RNAi screen reported online by the Drosophila RNAi Screening Center. Hence, our study is a persuasive example of how high-throughput RNAi databases of model organisms such as Drosophila can yield mechanistic insights into human disease. Apart from its pivotal role in T cell activation, NFAT1 mediates cytokine production in macrophages and DCs 30, 31 . LRRK2, which has high expression in myeloid cells and B cells but not in T cells, potently and dominantly inhibited translocation of NFAT1 to the nucleus. Biochemical analyses showed that LRRK2 did not regulate the phosphorylation of NFAT but instead participated in the NRON complex and directly inhibited the localization of NFAT1 to the nucleus. Thus, NFAT1 is controlled by two distinct steps, dephosphorylation by calcineurin and release by LRRK2 degradation, which may be governed by different stimuli such as Ca 2+ influx and LPS, respectively. This permits fine control of NFAT by microbial stimuli such as LPS and other ligands for Toll-like receptors that can induce the degradation of LRRK2, which might be critical for IBD. The lower LRRK2 expression in T cells than in macrophages, DCs and B cells may explain why this additional regulator of NFAT1 has eluded detection so far.
Abnormal NFAT1 activation has been observed in colon tissues from patients with IBD 37 . Furthermore, NFAT1 deficiency in mice suppresses CD4 + T cell-mediated, oxazolone-induced colitis 38 . Our study has shown that activation of NFAT1 in monocytic cells from Lrrk2 −/− mice exacerbated inflammation in DSS-induced colitis. Moreover, treatment with CsA suppressed NFAT1, which explains the well-known therapeutic effect of CsA on DSS-induced colitis. Aberrant NFAT1 activation is more prevalent in ulcerative colitis than in CD 37 . A meta-analysis of GWAS has shown that LRRK2 is also a common susceptibility gene for ulcerative colitis 6 . Although CD and ulcerative colitis have different disease manifestations, they are closely related in pathogenesis, and LRRK2 may be pathologically relevant to both.
LRRK2 has multiple functional domains, and its interaction with multiple components of the NRON complex suggests that it has a 'scaffold' function in intracellular regulation 39 . The linkage of LRRK2 to two apparently unrelated diseases, Parkinson's disease and IBD, is notable. The Parkinson's disease-related mutation G2019S results in more LRRK2 kinase activity, which disturbs cytoskeleton remodeling and microRNA regulation 40, 41 . In contrast, the IBD risk allele M2397 affected the accumulation of LRRK2 but left its kinase activity unaffected, which suggests that the pathogenic role of LRRK2 in each disease is distinct. Indeed, the kinase function of LRRK2 had no apparent effect on NFAT regulation. Notably, aberrant activation of microglia cells has been observed in 20-month-old Lrrk2 −/− mice but not in wild-type mice or mice with transgenic expression of LRRK2 (ref. 42) . It is possible that inhibition of NFAT by LRRK2 affects the activation of microglia during the pathogenesis of Parkinson's disease. As a multidomain protein, LRRK2 may have diverse regulatory functions. For example, there are reports that LRRK2 may control autophagy, but its role in this has been contested [43] [44] [45] . It is possible that LRRK2 could affect this process, given that various autophagyrelated genes have emerged as susceptibility loci for CD. However, we did not observe any difference in autophagy induction in mouse embryo fibroblasts derived from wild-type or Lrrk2 −/− mice (data not shown). In fact, among the various signaling factors we examined, including NFAT1, NF-κB and the kinases Erk1-Erk2, Jnk and p38, only the activation of NFAT1 was specifically altered in Lrrk2 −/− BMDMs. Also, wild-type and Lrrk2 −/− BMDMs showed differences in NFAT1-driven cytokine responses, which suggests that the effects of LRRK2 on CD are attributable mainly to NFAT1 signaling.
Among the many SNPs in the LRRK2 locus associated with IBD, most are located in noncoding regions, with the exception of the missense polymorphism rs3761863, which encodes the substitution of methione for threonine at amino acid position 2397 (ref.
2). The association of rs3761863 with CD could be due to linkage disequilibrium with the noncoding polymorphism rs11175593, but the probability of that is low because the meta-analysis involved CD cohorts from three populations 2 . Both the M2397 allele and the T2397 allele are common in the general population, which facilitated our analysis of LRRK2 ex vivo in cells from homozygous carriers. Biochemically, the LRRK2 Met2397 variant was slightly less stable as a protein. We measured less LRRK2 protein in peripheral B lymphocytes from people homozygous for the M2397 allele as well as a small but reproducible enhancement of NFAT function. Our preliminary evidence has indicated that macrophages from people homozygous for the M2397 allele also have more cytokine production in response to stimuli of the innate immune response such as zymosan, but those findings must be confirmed with more subjects. IBD is a complex disease with contributions from both genetic and environmental factors, and no single factor alone determines disease severity. Our observation that the effect of M2397 on the amount of LRRK2 was significant but subtle demonstrated that LRRK2 is part of a complex susceptibility genotype involving multiple independent loci 2, 3, 46 . GWAS have shown that the effect of common variants on disease susceptibility is typically modest 2, 3, 46 . Although susceptibility loci are generally presumed to alter the expression or stability of mRNA, our data have shown that they may have pathogenetic post-translational effects on the target proteins. A published report has shown that a single nucleotide change in IRGM, another gene linked to susceptibility to IBD, leads to altered autophagy by diminishing the amount of protein through the regulation of mRNA expression by microRNA 43 . Small effects on the amount of protein may warrant medical attention; for example, even though SNPs in the gene encoding the enzyme HMG-CoA reductase have only a 5% effect on the amount of low-density lipoprotein, drugs that target this enzyme have much larger quantitative effects on lowdensity lipoprotein and confer great health benefits 46 . In summary, LRRK2 could have a role in IBD as a regulator of NFAT1, which may lead to new pharmacological approaches to this disease. Our study of the role of LRRK2 in IBD also provides an example of how molecular studies after GWAS can provide additional insights into complex diseases such as IBD.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/natureimmunology/.
Note: Supplementary information is available on the Nature Immunology website. 
